Katherine Xu is currently the Partner and Co-Head of the Biopharmaceutical Equity Research Group at William Blair, based in New York. Prior to William Blair, Katherine was senior vice president and senior biotechnology analyst at Wedbush Securities, vice president and senior biotechnology analyst at Credit Suisse, and a senior biotechnology analyst at Pacific Growth Equities. Katherine was recognized by the Financial Times/StarMine World's Top Analysts listing, ranking No. 7 overall for stock-picking in the United States in 2010, and No. 2 for stock-picking in biotechnology in 2011; she received the No. 2 ranking in The Wall Street Journal's Best on the Street listing in 2011 as well. Before her move to equity research, Katherine worked in investment banking for two years. Katherine holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively. She attended Peking University in Beijing and Kalamazoo College in Michigan, where she gained her B.A. with honors.